Behavioral and cellular modulation of L-DOPA-induced dyskinesia by β-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 755-765

  Lindenbach, David ^a   Ostock, Corinne Y ^a   Eskow Jaunarajs, Karen L ^a   Dupre, Kristin B ^a   Barnum, Christopher J ^a   Bhide, Nirmal ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; LEVODOPA; OXIDOPAMINE; PROPRANOLOL;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSKINESIA; L DOPA INDUCED DYSKINESIA; MALE; MOTOR ACTIVITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MOLECULAR TARGETED THERAPY; MOTOR ACTIVITY; OXAZINES; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; TIME FACTORS;

EID: 79956197316     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179416     Document Type: Article

References (40)

1. Ahlskog JE and Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458. (Pubitemid 36041148)
2. Arai A, Tomiyama M, Kannari K, Kimura T, Suzuki C, Watanabe M, Kawarabayashi T, Shen H, and Shoji M (2008) Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse 62:632-635. (Pubitemid 351951301)
3. Barnum CJ, Eskow KL, Dupre K, Blandino P Jr., Deak T, and Bishop C (2008) Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemiparkinsonian rat: role for interleukin-1beta. Neuroscience 156:30-41.
4. Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, Fisone G, Nestler EJ, and Greengard P (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci USA 107: 14845-14850.
5. Bianchetti G, Elghozi JL, Gomeni R, Meyer P, and Morselli PL (1980) Kinetics of distribution of di-propranolol in various organs and discrete brain areas of the rat. J Pharmacol Exp Ther 214:682-687. (Pubitemid 10061419)
6. Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, and Walker PD (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res 87:1645-1658.
7. Bishop C, Tessmer JL, Ullrich T, Rice KC, and Walker PD (2004) Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J Pharmacol Exp Ther 310:687-694. (Pubitemid 38988914)
8. Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20:919-931.
9. 2 adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J Neurochem 112:444-452.
10. 1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Synapse 64: 117-126.
11. Carpentier AF, Bonnet AM, Vidailhet M, and Agid Y (1996) Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 46:1548-1551. (Pubitemid 26185769)
12. Carta M, Carlsson T, Kirik D, and Björklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833. (Pubitemid 47343795)
13. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243.
14. Cenci MA, Lee CS, and Björklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706. (Pubitemid 28362576)
15. Cenci MA and Lundblad M (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9:Unit 9.25.
16. Chang JW, Wachtel SR, Young D, and Kang UJ (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617-628. (Pubitemid 28480020)
17. Colosimo C and Craus A (2003) Noradrenergic drugs for levodopa-induced dyskinesia. Clin Neuropharmacol 26:299-305. (Pubitemid 37505436)
18. Dekundy A, Lundblad M, Danysz W, and Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76-89. (Pubitemid 46441485)
19. 1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 55:1321-1328.
20. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, and Bishop C (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63:610-620.
21. Eskow KL, Gupta V, Alam S, Park JY, and Bishop C (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of L-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy. Pharmacol Biochem Behav 87:306-314. (Pubitemid 47101876)
22. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, and Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432. (Pubitemid 120031867)
23. Gomez-Mancilla B and Bédard PJ (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427. (Pubitemid 23292096)
24. Goshima Y, Misu Y, Arai N, and Misugi K (1991) Nanomolar L-dopa facilitates release of dopamine via presynaptic β-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease. Jpn J Pharmacol 55:93-100.
25. Hara M, Fukui R, Hieda E, Kuroiwa M, Bateup HS, Kano T, Greengard P, and Nishi A (2010) Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons. J Neurochem 113:1046-1059.
26. Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368-376.
27. Kilpatrick IC, Jones MW, and Phillipson OT (1986) A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876. (Pubitemid 16095494)
28. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, and Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132. (Pubitemid 35478015)
29. Matthews JC and Baker JK (1982) Effects of propranolol and a number of its analogues on sodium channels. Biochem Pharmacol 31:1681-1685. (Pubitemid 12102559)
30. Mehvar R and Brocks DR (2001) Stereospecific pharmacokinetics and pharmacodynamics of β-adrenergic blockers in humans. J Pharm Pharm Sci 4:185-200. (Pubitemid 34305610)
31. 3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol. Eur J Pharmacol 101:289-293.
32. Oka H, Morita M, Onouchi K, Yoshioka M, Mochio S, and Inoue K (2007) Cardiovascular autonomic dysfunction in dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 254:72-77. (Pubitemid 46330412)
33. Paxinos G and Watson W (1998) The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego, CA.
34. 2-adrenergic receptors in rat brain. Proc Natl Acad Sci USA 81:1585-1589.
35. Reisine TD, Chesselet MF, Lubetzki C, Chéramy A, and Glowinski J (1982) A role for striatal beta-adrenergic receptors in the regulation of dopamine release. Brain Res 241:123-130. (Pubitemid 12124936)
36. Rommelfanger KS and Weinshenker D (2007) Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74:177-190. (Pubitemid 46890808)
37. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Hervé D, Greengard P, and Fisone G (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27:6995-7005. (Pubitemid 47015907)
38. 2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18:872-883.
39. Waeber C, Rigo M, Chinaglia G, Probst A, and Palacios JM (1991) β-Adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease. Synapse 8:270-280.
40. Winkler C, Kirik D, Björklund A, and Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186.